title: Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in heterozygotes for lipoprotein lipase deficiency.
abstract: We have assessed the expression of heterozygosity for lipoprotein lipase (LPL) deficiency by studying a single large French Canadian family comprising 92 persons including 21 carriers of the catalytically defective P207L mutation. Phenotypic changes distinguishing heterozygotes from controls were seen early, before the age of 40 and often before 20 years of age. In the total cohort these changes included an elevation in the mean very low density (VLDL) and intermediate density lipoprotein (IDL) triglyceride (+69%; P = 0.01 and +40%; P = 0.001) and cholesterol (+51%; P = 0.03 and +67%; P = 0.007) and apoB levels but decreased HDL2 and HDL3 cholesterol, (-32%; P = 0.01 and -15%; P = 0.002 respectively). While the lipid compositions of VLDL and IDL were similar between heterozygotes and controls, the low density (LDL) and high density lipoproteins (HDL) of carriers were triglyceride enriched. Heterozygotes also had a markedly lower apoC-III ratio (apoC-III in supernatant/apoC-III in heparin precipitate) (1.46 vs. 3.86 P = 1 x 10(-4)) indicating a substantial enrichment of VLDL and IDL with apoC-III and depletion of HDL apoC-III supporting this ratio as an effective index for efficiency of lipolysis. LpA-I was markedly reduced (0.34 vs. 0.43 P = 1 x 10(-5)) showing that levels of this particle are partly dependent on LPL catalytic activity. Heterozygotes manifest from an early age with a markedly reduced HDL, LpA-I, apoC-III ratio and an increased TC/HDLc ratio which would predict a relatively increased risk of premature coronary artery disease, compared to their normal siblings.
authors.affiliation: Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Bijvoet
authors.forename: S E
authors.initials: SE
authors.lastname: Gagné
authors.forename: S
authors.initials: S
authors.lastname: Moorjani
authors.forename: C
authors.initials: C
authors.lastname: Gagné
authors.forename: H E
authors.initials: HE
authors.lastname: Henderson
authors.forename: J C
authors.initials: JC
authors.lastname: Fruchart
authors.forename: J
authors.initials: J
authors.lastname: Dallongeville
authors.forename: P
authors.initials: P
authors.lastname: Alaupovic
authors.forename: M
authors.initials: M
authors.lastname: Prins
authors.forename: J J
authors.initials: JJ
authors.lastname: Kastelein
authors.forename: M R
authors.initials: MR
authors.lastname: Hayden
mesh_terms: D000328:Adult; D000375:Aging; D001053:Apolipoproteins / Q000097:blood*; D002648:Child; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D005260:Female; D006579:Heterozygote; D006801:Humans; D008072:Hyperlipoproteinemia Type I / Q000097:blood* / Q000235:genetics*; D008071:Lipoprotein Lipase / Q000172:deficiency / Q000235:genetics*; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010375:Pedigree; D010641:Phenotype; D011792:Quebec; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D002784:Cholesterol; D008071:Lipoprotein Lipase